^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 amplification

    i
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer (NRG-GY026) (NCT05256225)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/16/2022
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    HER-2 • TP53
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations (NCT06043713)
    Phase 1
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/15/2023
    Primary completion :
    12/31/2025
    Completion :
    02/09/2026
    HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (NCI-2021-11793) (NCT05111561)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/21/2025
    Initiation :
    08/02/2022
    Primary completion :
    03/14/2025
    Completion :
    03/14/2025
    HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1
    |
    BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion
    |
    Mektovi (binimetinib) • ZEN-3694
    QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109)
    Phase 2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/01/2018
    Primary completion :
    06/01/2020
    Completion :
    02/09/2022
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (NCT04345913)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    ER • PIK3CA • PGR • PTEN
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation
    |
    Halaven (eribulin mesylate) • Aliqopa (copanlisib)
    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    08/09/2021
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    HER-2 • TP53 • ATM • RAS • CD4
    |
    HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
    Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas (NCT04620187)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/24/2020
    Primary completion :
    02/01/2026
    Completion :
    02/01/2027
    HER-2
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine)
    Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors (KEYNOTE-E34) (NCT05784688)
    Phase 1/2
    TiumBio Co., Ltd.
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    03/10/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    EGFR • KRAS • BRAF • NRAS
    |
    BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • NCE 401
    Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (NCT05845450)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    05/11/2023
    Primary completion :
    05/01/2026
    Completion :
    05/01/2028
    HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1
    |
    HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer) (NCT05415215)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/05/2022
    Primary completion :
    11/20/2024
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 amplification • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma (NCT05943795)
    Phase 3
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK
    |
    KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion
    |
    docetaxel • izalontamab (SI-B001)
    Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (NCT02779855)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    05/02/2017
    Primary completion :
    09/20/2020
    Completion :
    03/31/2025
    HER-2 • ER • PGR
    |
    HER-2 amplification
    |
    paclitaxel • Imlygic (talimogene laherparepvec)
    Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. (NCT00950742)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    08/01/2009
    Primary completion :
    10/01/2013
    Completion :
    10/01/2013
    HER-2
    |
    HER-2 amplification
    |
    Herceptin (trastuzumab) • Gilotrif (afatinib)
    Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) (BEAMION-Lung 1) (NCT04886804)
    Phase 1
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/02/2021
    Primary completion :
    03/31/2026
    Completion :
    01/28/2028
    NRG1
    |
    EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation
    |
    zongertinib (BI 1810631)
    Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (NCI-2018-01218) (NCT03065387)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/31/2017
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    HER-2 • KRAS • ERBB3 • ERBB4
    |
    KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)
    Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (NCT00436254)
    Phase 1
    University of Washington
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/01/2001
    Primary completion :
    03/01/2010
    Completion :
    04/01/2025
    HER-2 • MUC16
    |
    HER-2 overexpression • HER-2 amplification
    |
    AST-301 • Leukine (sargramostim)
    HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (NCT03696030)
    Phase 1
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/31/2018
    Primary completion :
    03/11/2025
    Completion :
    03/11/2025
    HER-2
    |
    HER-2 amplification
    |
    MB-103
    Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (CALGB-40601) (NCT00770809)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/01/2008
    Primary completion :
    01/31/2014
    Completion :
    07/10/2025
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • lapatinib • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)
    Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (SGNTUC 024) (NCT04430738)
    Phase 1/2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/15/2020
    Primary completion :
    07/31/2024
    Completion :
    10/31/2025
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium
    Tucatinib Together with Pembrolizumab and Trastuzumab (TUGETHER) (NCT04789096)
    Phase 2
    Breast Cancer Trials, Australia and New Zealand
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    03/07/2023
    Primary completion :
    09/30/2025
    Completion :
    09/01/2026
    HER-2 • PD-L1
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)
    Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/17/2020
    Primary completion :
    06/22/2023
    Completion :
    07/16/2025
    HER-2 • ER • PIK3CA • PGR • PTEN
    |
    HER-2 amplification • HER-2 negative • PGR positive
    |
    Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)
    Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (NCT04574583)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/03/2025
    Initiation :
    11/24/2020
    Primary completion :
    02/07/2023
    Completion :
    05/19/2023
    HER-2 • PD-L1 • ER • PGR • CD4
    |
    HER-2 amplification • HER-2 negative
    |
    bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
    Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer (NCT04294628)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/01/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    CD4
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (SWOG S1613) (NCT03365882)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    11/27/2017
    Primary completion :
    11/01/2022
    Completion :
    11/30/2025
    HER-2 • KRAS • BRAF • NRAS
    |
    BRAF V600E • HER-2 amplification • BRAF V600
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)
    Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (NCT03125928)
    Phase 2
    Fox Chase Cancer Center
    Active, not recruiting
    Last update posted :
    01/10/2025
    Initiation :
    06/13/2017
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab)
    A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (NCT04024462)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    12/20/2024
    Initiation :
    02/05/2020
    Primary completion :
    12/13/2021
    Completion :
    11/11/2025
    PIK3CA
    |
    HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive
    |
    Herceptin (trastuzumab) • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • cyclophosphamide intravenous
    OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease (NCT03487666)
    Phase 2
    Georgetown University
    Completed
    Last update posted :
    12/03/2024
    Initiation :
    05/21/2018
    Primary completion :
    11/03/2021
    Completion :
    05/02/2024
    HER-2
    |
    HER-2 amplification • HER-2 negative
    |
    Opdivo (nivolumab) • capecitabine
    A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment with Trastuzumab Combined with Parezumab (NCT05760612)
    Phase 3
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Recruiting
    Last update posted :
    11/28/2024
    Initiation :
    03/14/2023
    Primary completion :
    02/16/2028
    Completion :
    11/01/2028
    HER-2 • ER • PGR
    |
    HER-2 positive • HR positive • HER-2 amplification • HER-2 amplification + HR-positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • Perjeta (pertuzumab)
    Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction (NCT05480384)
    Phase 2
    Brown University
    Recruiting
    Last update posted :
    11/25/2024
    Initiation :
    07/14/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer (NCT03414658)
    Phase 2
    Adrienne G. Waks
    Active, not recruiting
    Last update posted :
    11/06/2024
    Initiation :
    06/21/2018
    Primary completion :
    05/01/2023
    Completion :
    05/31/2025
    HER-2 • PD-L1
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Bavencio (avelumab) • vinorelbine tartrate • utomilumab (PF-05082566)
    Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer (BTCRC-BRE19-409) (NCT04762979)
    Phase 2
    Marina N Sharifi
    Recruiting
    Last update posted :
    10/30/2024
    Initiation :
    02/12/2021
    Primary completion :
    09/01/2025
    Completion :
    01/01/2026
    HER-2 • PIK3CA
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative
    |
    Piqray (alpelisib) • fulvestrant
    Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) (NCT04704934)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    10/24/2024
    Initiation :
    05/21/2021
    Primary completion :
    10/01/2025
    Completion :
    02/01/2026
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab)
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (DB-1303-O-1001) (NCT05150691)
    Phase 1/2
    DualityBio Inc.
    Recruiting
    Last update posted :
    10/03/2024
    Initiation :
    01/31/2022
    Primary completion :
    04/01/2026
    Completion :
    10/01/2027
    HER-2
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Perjeta (pertuzumab) • trastuzumab pamirtecan (BNT323) • itraconazole • ritonavir
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (NCT04147819)
    Phase 1
    Bayer
    Completed
    Last update posted :
    09/27/2024
    Initiation :
    07/02/2020
    Primary completion :
    08/21/2023
    Completion :
    09/26/2023
    HER-2
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439 • BAY2701438
    Niraparib + Dostarlimab in BRCA Mutated Breast Cancer (TBCRC 056) (NCT04584255)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    09/19/2024
    Initiation :
    12/18/2020
    Primary completion :
    07/17/2025
    Completion :
    07/17/2029
    HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Basket Study for Oligo-metastatic Breast Cancer (ANISE) (NCT05982678)
    Phase 2
    The Netherlands Cancer Institute
    Recruiting
    Last update posted :
    08/21/2024
    Initiation :
    05/02/2024
    Primary completion :
    10/01/2027
    Completion :
    10/01/2034
    HER-2 • ER
    |
    HER-2 positive • HER-2 amplification
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (NCT03789110)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    08/20/2024
    Initiation :
    03/08/2019
    Primary completion :
    09/30/2021
    Completion :
    12/30/2024
    HER-2 • PGR • TMB
    |
    HR positive • HER-2 amplification • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (NCT02326974)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    08/07/2024
    Initiation :
    01/01/2015
    Primary completion :
    06/01/2018
    Completion :
    01/01/2028
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)